910332-55-7

Basic information

• Product Name: 3-[4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonylamino]-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester
• Synonyms: 3-[4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonylamino]-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester
• CAS NO: 910332-55-7
• Molecular Weight: 583.706
• Mol File: 910332-55-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-[4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonylamino]-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonylamino]-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester(910332-55-7)
• EPA Substance Registry System: 3-[4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonylamino]-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester(910332-55-7)

Safety Data

• Hazardous Substances Data: 910332-55-7(Hazardous Substances Data)

Upstream product

• 477585-31-2 4-(2-methylquinolin-4-ylmethoxy)benzenesulfonyl chloride hydrochloride salt 
• 910332-54-6 3-amino-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester 

Downstream Products

• 910332-56-8 3-[4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonylamino]-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 

Relevant articles and documents

Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase

This invention provides compounds of Formula I, having the structure: that are useful in treating diseases or disorders mediated by TNF-α, such as arthritis (rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, osteoarthritis etc), tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection, ankylosing spondylitis, psoriasis, sepsis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, asthma, idiopathic pulmonary fibrosis, vasculitis, systemic lupus erythematosus, irritable bowel syndrome, acute coronary syndrome, hepatitis C, cachexia, COPD, stroke or type 2 diabetes, and for alleviation of symptoms thereof. The invention further provides methods for use of the compounds.